Femme Homme
- | Pays :
- France
- | Organes : -
- | Spécialités : -
Extrait
The objective of this randomized phase II is to evaluate the benefit of regorafenib for ovarian patients who reported a confirmed elevated CA-125 level under surveillance or bevacizumab, compared with tamoxifen.
Critère d'inclusion
- Ovarian Carcinoma